A Multi-Part, Phase 3, Randomized, Observer Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adults Previously Vaccinated With Other COVID-19 Vaccines

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs COVID-19 vaccine adjuvanted Novavax (Primary) ; NVX CoV2540 (Primary) ; NVX-CoV2515 (Primary)
Indications COVID 2019 infections
Focus Pharmacodynamics; Registrational
Acronyms COVID-19
Sponsors Novavax

Most Recent Events

01 Jun 2024 Interim Results (n=837) assessing immunogenicity and safety outcomes after one booster dose published in The Lancet Infectious Diseases
19 Apr 2024 Status changed from active, no longer recruiting to completed.
16 Nov 2023 Results assessing antibody responses to SARS-CoV-2 , published in the Journal of Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight